RM2 antigen (β1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer

International Journal of Cancer

Volumn 115, Issue 1, 2005, Pages 105-113

  Saito, Seiichi ^a   Egawa, Shin ^b   Endoh, Mareyuki ^a   Ueno, Seiji ^a   Ito, Akihiro ^a   Numahata, Kenji ^a   Satoh, Makoto ^a   Kuwao, Sadahito ^c   Baba, Shiro ^c   Hakomori, Senitiroh ^d,e,f   Arai, Yoichi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f PNRI   (United States)

Author keywords

Gleason score; Glycoprotein; Marker; Prostate cancer; RM2 antigen

Indexed keywords

CARBOHYDRATE ANTIGEN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RM2; PROSTATE SPECIFIC ANTIGEN; RM2 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN; CARBOHYDRATE; RM2 ANTIGEN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE MARKER; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; CARBOHYDRATE ANALYSIS; CHEMISTRY; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; MOLECULAR GENETICS; PROSTATE TUMOR; TIME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BLOTTING, WESTERN; CARBOHYDRATE SEQUENCE; CARBOHYDRATES; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 20244376920     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20868     Document Type: Article

References (33)

1. Carter HB, Partin AW. Diagnosis and staging of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's urology, 8th ed. Philadelphia: Saunders, 2002, 3209-26.
2. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003;30:677-86.
3. Canto EI, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003;30:263-77.
4. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002;167:528-34.
5. Ellis DW, Leffers S, Dvies JS, Ng ABP. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol 1984;81:279-84.
6. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostatic specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-52.
7. Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KB, Badaro R, Reed SG. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 2000;60:1677-82.
8. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
9. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB. Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-8.
10. Ayala G, Wang D, Wulf G, Frolov A, Li R, Sowadski J, Wheeler TM, Lu KP, Bao L. The prolyl isomerase Pin 1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003;63:6244-51.
11. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
12. Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes J, Schellhammer PF, Yasui Y, Feng Z, Wright GL. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
13. Nam RK, Diamandis EP, Toi A, Tranchtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MAS, Narad SA. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000;18:1035-42.
14. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257-331.
15. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
16. Zhang S, Zhang HS, Reuter VE, Slovin HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancer. Clin Cancer Res 1998;4:295-302.
17. Saito S, Orikasa S, Ohyama C, Satoh M, Fukushi Y. Changes in glycolipids in human renal-cell carcinoma and their clinical significance. Int J Cancer 1991;49:329-34.
18. Saito S, Levery SB, Salyan MEK, Goldberg RI, Hakomori S. Common tetrasaccharide epitope NeuAcα2→3Galβ1→3(NeuAcα 2→ 6)GalNAc. presented by different carrier glycosylceramides or O-linked peptides, is recognized by different antibodies and ligands having distinct specificities. J Biol Chem 1994;269:5644-52.
19. Ito A, Levery SB, Saito S, Satoh M, Hakomori S. A novel ganglioside isolated from renal cell carcinoma. J Biol Chem 2001;276:16695-703.
20. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. In: Kleihues P, Sobin LH, eds. World Health Organization classification of tumours. Lyon: IARC Press. 2004, 179-84.
21. Saito S, Orikasa S, Satoh M, Ohyama C, Ito A, Takahashi T. Expression of globo-series gangliosides in human renal cell carcinoma. Jpn J Cancer Res 1997:652-9.
22. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92.
23. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-7.
24. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer. Am J Surg Pathol 2001;25:657-60.
25. Salomon L, Asantasiadis AG, Johnson CW, McKiernan JM, Goluboff ET, Abbou CC, Olsson CA, Benson MC. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 2003;62:304-9.
26. Wu JD, Higgins KM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-8.
27. Ito A, Saito S, Masuko T, Oh-eda M, Matsuura T, Satoh M, Moosavi Nejad F, Enomoto T, Orikasa S, Hakomori S. Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues. Glycoconj J 2001;18:475-85.
28. Satoh M, Moosavi Nejad F, Nakano O, Ito A, Kawamura S, Ohyama C, Saito S, Orikasa S. Four new human renal cell carcinoma cell lines expressing globo-series gangliosides. Tohoku J Exp Med 1999;189:95-105.
29. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903.
30. Hakomori S. Possible functions of tumor-associated carbohydrate antigens. Curr Opin Immunol 1991;3:646-53.
31. diSant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Cancer 1992;70:254-68.
32. Abrahamsson P-A. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999;6:503-19.
33. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part 1. A clinicopathological study of 20 cases. Cancer 1987;59:1803-9.